Atai Life Sciences SG&A Expenses 2020-2024 | ATAI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Atai Life Sciences sg&a expenses from 2020 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Atai Life Sciences sg&a expenses from 2020 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Fresenius SE (FSNUY)	$21.4B
Quest Diagnostics (DGX)	$17.3B
DaVita (DVA)	$13.7B
Encompass Health (EHC)	$9.3B
Chemed (CHE)	$8.7B
Elanco Animal Health (ELAN)	$7.2B
Option Care Health (OPCH)	$5.3B
RadNet (RDNT)	$5B
Amedisys (AMED)	$3.2B
Astrana Health (ASTH)	$2.8B
LifeStance Health (LFST)	$2.6B
Addus HomeCare (ADUS)	$2.4B
U.S Physical Therapy (USPH)	$1.3B
Pennant (PNTG)	$1.1B
Aveanna Healthcare Holdings (AVAH)	$1B
Daxor (DXR)	$45M
ATI Physical Therapy (ATIP)	$25M
MEDIROM Healthcare Technologies (MRM)	$19M
Psychemedics (PMD)	$14M
Ontrak (OTRK)	$10M
Novo Integrated Sciences (NVOS)	$6M
IMAC Holdings (BACK)	$2M